Adverse Event reporting information can be found in footer

Request a Meeting

RESOURCES FOR USE WITH YOUR PATIENTS

ULCERATIVE COLITIS AND CORTIMENT® PATIENT LEAFLET

Support your patients prescribed CORTIMENT® to treat their UC by simply emailing a link to this leaflet which contains FAQs such as:

  • Why have I been prescribed CORTIMENT®?
  • What is the difference between systemic steroids and CORTIMENT®?
  • How and when to take CORTIMENT®

MICROSCOPIC COLITIS AND CORTIMENT® PATIENT LEAFLET

Support your patients prescribed CORTIMENT® to treat their MC by simply emailing a link to this leaflet which contains FAQs such as:

  • What is Microscopic Colitis?
  • Why have I been prescribed CORTIMENT®?
  • How and when to take CORTIMENT®

CORTIMENT® Product Monograph

The CORTIMENT Product Monograph contains a comprehensive overview of CORTIMENT’s use within its licensed therapeutic areas. You will find information on Ulcerative and Microscopic Colitis, the rationale for CORTIMENT’s development, its mechanism of action, and clinical data from randomised controlled trials and real world evidence.

CORE PRACTICE STUDY

The CORE Practice is a Real World Evidence study published by Danese S, et al. J Crohns Colitis. 2019;13(supplement 1):296-297

This looks at results from a prospective, multi-centre, observational cohort study assessing the effectiveness of CORTIMENT® for mild to moderate active UC.

iSTART Paper

iSTART (iSupport Therapy-Access to Rapid Treatment) is a Ferring Pharmaceuticals initiative consisting of a global expert panel to improve patient-centred management for mild to moderate UC.

GUIDANCE ON PRESCRIBING CORTIMENT® BY BRAND

This leaflet provides useful information including:

  • The differences between MMX and non-MMX budesonides
  • Writing the correct name on the script to ensure Cortiment® is dispensed

INTERNATIONAL REAL WORLD EVIDENCE

This leaflet provides a summary of key Real World Evidence studies using CORTIMENT®for the treatment of flaring Ulcerative Colitis:

  • International CORE Practice study Danese et al. 2019
  • National Audit Kearns et al. 2020

CORTIMENT® – TREATMENT FOR MICROSCOPIC COLITIS

This leaflet provides an overview of Microscopic Colitis and how CORTIMENT® can be used to treat patients with Active Microscopic Colitis

  • Harbord M, et al. J Crohns Colitis. 2017;11(7):769–784.
  • Cortiment 9 mg, Prolonged Release Tablets. SmPC.
  • Entocort CR 3mg Capsules. SmPC.
  • Budenofalk 3 mg Gastro-resistant Capsules. SmPC.
  • Budenofalk 9 mg Gastro-resistant Granules. SmPC.
  • National Institute for Health Care Excellence (NICE) Frequently asked questions – clinical. Available from https://bnf.nice.org.uk/about/frequently-asked-questionsclinical.html. Last accessed October 2018.

Job Code: UK-COR-2200064 - Date of preparation: November 2022

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.